Tanzisertib Hydrochloride (CC-930)

Tanzisertib HCl (CC-930) inhibits the formation of phospho-cJun in human PBMC stimulated by phorbol-12-myristate-13-acetate and phytohemeagglutinin (IC50 = 1 μM). It shows remarkable selectivity in a panel of 240 kinases, EGFR being the only non-MAP kinase inhibited more than 50% at 3 μM (IC50 = 0.38 μM). This compound inhibits no receptor at greater than 50% at 10 μM concentration in a panel of 75 receptors, ion channels and neurotransmitter transporters. It does not inhibit CYP P450 enzymes significantly and is metabolized by CYP 3A4 and 2D6[1].

In the acute rat LPS-induced TNFα production PK-PD model, Tanzisertib HCl (CC-930) inhibits the production of TNFα by 23% and 77% at 10 and 30 mg/kg oral dose respectively. It is well-tolerated and exposure is dose-proportional[1].

Jurkat T cells (5×10⁵ /well) are aliquoted in 96 well membrane filter plates, then treated with or without Tanzisertib HCl (CC-930) 30 minutes prior to stimulation with 0.3 μg/ml anisomycin for an additional 40 minutes. Cells are pelleted under vacuum with plate manifold. Cell lysates are prepared by adding 75 μl/well lysis buffer (20 mM HEPES pH 7.4, 100 mM NaCl, 0.2% Triton X-100, 0.5 mM DTT, 2x phosphatase inhibitors, 20 mM PNPP, 1x protease inhibitors), for 30 minutes at room temperature. Lysates are filtered and collected into a new 96 well plate placed beneath the vacuum manifold. Cell lysates (45 μl) are added to an assay plate containing bound GST-c-Jun and MgCl2 in solution (10 mM) then incubated for 10 minutes at room temperature. The reaction is stopped by washing with Tris-buffered saline containing 0.02% Tween 20 and the phosphorylated GST-c-Jun detected by Europium labeled anti-phospho-c-Jun, DELFIA assay buffer and enhancement solution. Plate fluorescence is measured.

• https://pubmed.ncbi.nlm.nih.gov/22244937/